320 HATCH DRIVE, FOSTER CITY, CA
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Material disclosure
Costs of Shutting Down or Selling Parts of the Business
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Announces CEO Transition
Volasertib Development Program to Improve the Standard of Care for Patients with Acute Myeloid Leukemia
Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study
Q2
Q1
FY 2023
Notice of Late Filing for Annual Report
Q3
FY 2022
Amended Registration Statement for Securities
S-1
Registration Statement for Securities to be Offered to Employees
RW
Registration Statement for Securities Offered under a Shelf Registration
Prospectus Filed Pursuant to Rule 425
Definitive Proxy Statement
PRE 14A
Notification Filed by a National Security Exchange
Initial Statement of Beneficial Ownership
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
SEC Staff Action Letter
SEC Staff Correspondence
Correspondence
Submission Upload